在心力衰竭 (VOID-HF) 中结合负压尿液的体积优化
Alex M Parker1, Vincent G Bird2, Shweta Bansal3
1From the Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida.
概括
在JuxtaFlow脏辅助器件 (RAD) 早期显示在治疗急性失补心力衰竭的治疗利尿剂耐药的承诺. 这种新疗法在一项小型试验中改善了尿液输出和分泌,表明了管理心力衰竭拥堵的潜力.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 医疗器械 医疗器械
背景情况:
- 急性不补偿性心力衰竭 (ADHF) 经常涉及由于心脏病综合征而导致的尿液抵抗.
- 在有尿素耐药的ADHF患者中管理液体过载仍然是一个临床挑战.
研究的目的:
- 评估JuxtaFlow脏辅助装置 (RAD) 的安全性和可行性,用于治疗尿剂耐药ADHF患者的血栓塞.
- 评估RAD在改善尿量和功能标志物的有效性.
主要方法:
- 一个开放标签,单臂试验 (VOID-HF) 涉及七名患有ADHF和利尿剂耐药性的患者.
- 用于24小时治疗的RAD导管系统植入,具有主要安全性终点 (血) 和次要疗效终点 (尿液输出,脏生物标志物).
主要成果:
- 在七名患者中,有六名在超声波上完成了该方案,没有脏结构异常.
- 观察到24小时尿量和分泌量的显著改善.
- 在这个患者队列中,RAD系统在早期证明了可行性.
结论:
- 该JuxtaFlow RAD显示早期可行性,用于管理阻尿ADHF的拥堵.
- 需要进一步的研究来确定RAD作为潜在的治疗选择的安全性和有效性.
相关概念视频
Heart Failure Drugs: Diuretics
277
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
277
Antihypertensive Drugs: Action of Diuretics
570
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
570
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Antihypertensive Drugs: Potassium-Sparing Diuretics
398
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
398
Heart Failure Drugs: β-Blockers
259
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K


